Published in Gene Therapy Weekly, February 26th, 2004
Under the terms of the agreement, Insmed will obtain worldwide rights in territories (excluding Japan) where a valid patent claim exists, including the United States and Europe. Financial terms were not disclosed.
Seiji Hashimoto, PhD, director, product planning, global corporate strategic planning of Fujisawa, stated, "Severe insulin resistance can be a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.